Novel MET Amplification-Targeting Small-Molecule Kinase Inhibitor (HJ-462 BIC)

HJ-462 features protein kinase inhibitors with ingenious molecular designs that avoid defects in drug metabolism within the body, resulting in excellent safety and remarkable efficacy(achieving 100% tumor regression in liver cancer, gastric cancer, and lung cancer models caused by MET amplification, effectively curing these conditions).